Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 5, 2021

Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn

Clinical-stage biotechnology company Amgen has signed an agreement to acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of around $1.9bn. 

Credit: Miguel Á. Padriñán from Pixabay